Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Peresolimab or LY3509754 in Psoriasis
NCT04152382Phase 1Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2019
- Primary completion
- Feb 2022
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of peresolimab and LY3509754 in psoriasis (6 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants with One or More Serious Adverse Event(s) at 16 weeks. Started Nov 2019; status: terminated.
02
Drugs
peresolimabLY3509754
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT04152382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04152382.